Discharge medications (only hospital survivors)
| PAD | Non-PAD | Entire population | Missing n (%) | P value | |
| DAPT n (%) | 3050 (77.2) | 87 052 (83.9) | 90 102 (83.7) | 294 (0.3) | <0.001 |
| Aspirin n (%) | 3686 (93.3) | 99 068 (93.3) | 102 754 (95.4) | 134 (0.1) | <0.001 |
| P2Y12 inhibitor n (%) types | 3223 (81.5) | 89 907 (86.7) | 93 130 (86.5) | 160 (0.2) | <0.001 |
| Clopidogrel | 2696 (68.2) | 71 170 (68.6) | 73 866 (68.6) | ||
| Prasugrel | 30 (0.8) | 1612 (1.6) | 1642 (1.5) | ||
| Ticagrelor | 473 (12.0) | 16 609 (16.0) | 17 082 (15.9) | ||
| Anticoagulants n (%) types | 369 (9.3) | 3777 (3.6) | 4146 (3.9) | 725 (0.7) | <0.001 |
| Warfarin | 366 (9.3) | 3700 (3.6) | 4066 (3.8) | ||
| Dabigatran | 2 (0.05) | 46 (0.04) | 48 (0.04) | ||
| Rivaroxaban | 1 (0.03) | 14 (0.01) | 15 (0.01) | ||
| ACEi/ARB n (%) | 3044 (77.0) | 78 897 (76.1) | 81 942 (76.1) | 1465 (1.4) | 0.172 |
| Beta blockers n (%) | 3531 (89.3) | 93 873 (90.5) | 97 404 (90.5) | 149 (0.1) | 0.022 |
| Calcium antagonists n (%) | 1073 (27.1) | 13 797 (13.3) | 14 870 (13.8) | 170 (0.2) | <0.001 |
| Digitalis n (%) | 151 (3.8) | 1852 (1.8) | 2003 (1.9) | 151 (0.1) | <0.001 |
| Diuretics n (%) | 1791 (45.3) | 23 446 (22.6) | 25 237 (23.4) | 159 (0.2) | <0.001 |
| Statins n (%) | 3556 (90.0) | 96 649 (93.2) | 100 205 (93.1) | 161 (0.2) | <0.001 |
| Other lipid lowering agents n (%) types | 122 (3.1) | 1289 (1.2) | 1411 (1.3) | 1193 (1.1) | <0.001 |
| Ezetimibe | 95 (2.4) | 978 (0.9) | 1073 (1.0) | ||
| Fibrates | 13 (0.3) | 156 (0.2) | 169 (0.2) |
ACEi, ACE inhibitor;ARB, angiotensin II receptor blocker;DAPT, dual antiplatelet therapy (aspirin and P2Y12 inhibitor);PAD, peripheral artery disease.